OHSU

IRB #

IRB00009401

Title

A multicenter, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)

Principal Investigator

Roger Dailey

Study Purpose

The purpose of this study is to obtain information on the safety and effectiveness of an investigational drug called RV 001 in the treatment of Thyroid Eye Disease (TED).

Medical Condition(s)

Thyroid Eye Disease (TED)

Eligibility Criteria

1. Aged 18-75 years
2. Clinical diagnosis of Graves' disease associated with active TED within past 9 months
4. No previous medical or surgical therapy for TED, excluding local supportive measures.

Age Range

18 - 75

Healthy Volunteers Needed

No

Duration of Participation

Approximately 18 months

Minors Included

No

Contact

Chad Sorenson -
503-494-9633
sorensoc@ohsu.edu

Sponsor

River Vision Development Corporation

Recruitment End

12/13/2014

Compensation Provided

Yes

Compensation

$50 per study related visit


Go Back